PMID- 17445158
OWN - NLM
STAT- MEDLINE
DCOM- 20070621
LR  - 20130207
IS  - 0001-2815 (Print)
IS  - 0001-2815 (Linking)
VI  - 69 Suppl 1
DP  - 2007 Apr
TI  - Clinical significance of donor-recipient HLA matching on survival after 
      myeloablative hematopoietic cell transplantation from unrelated donors.
PG  - 25-30
AB  - The application of unrelated donor hematopoietic cell transplantation can be 
      expanded with the use of mismatched donors if human leukocyte antigen (HLA) 
      disparity does not lead to increased morbidity and mortality. The rules that 
      govern permissibility of HLA mismatches are not well defined. The International 
      Histocompatibility Working Group in hematopoietic cell transplantation measured 
      the risks associated with locus-specific disparity in 4796 patients transplanted 
      for low, intermediate, or high-risk hematologic diseases. The permissibility of a 
      given HLA mismatch is in part defined by the locus and by disease risk.
FAU - Petersdorf, E W
AU  - Petersdorf EW
AD  - Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, 
      WA98109, USA. epeters@fhcrc.org
FAU - Gooley, T
AU  - Gooley T
FAU - Malkki, M
AU  - Malkki M
FAU - Horowitz, M
AU  - Horowitz M
CN  - International Histocompatibility Working Group in Hematopoietic Cell 
      Transplantation
LA  - eng
GR  - AI 49213/AI/NIAID NIH HHS/United States
GR  - AI069197/AI/NIAID NIH HHS/United States
GR  - AI33484/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Blood Donors
MH  - Child
MH  - Child, Preschool
MH  - Donor Selection
MH  - Female
MH  - *Graft Survival
MH  - Graft vs Host Disease/etiology
MH  - HLA Antigens/*blood
MH  - Haplotypes
MH  - Hematologic Neoplasms/complications/mortality/therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Testing/*methods/mortality
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Transplantation
MH  - Treatment Outcome
EDAT- 2007/04/21 09:00
MHDA- 2007/06/22 09:00
CRDT- 2007/04/21 09:00
PHST- 2007/04/21 09:00 [pubmed]
PHST- 2007/06/22 09:00 [medline]
PHST- 2007/04/21 09:00 [entrez]
AID - TAN759_2 [pii]
AID - 10.1111/j.1399-0039.2006.759_2.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2007 Apr;69 Suppl 1:25-30. doi: 
      10.1111/j.1399-0039.2006.759_2.x.